Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRP | O00591 | 1/20 | 0.62 |
| ▸ | GABRD | O14764 | 1/20 | 0.62 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.62 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.62 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.62 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.62 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.62 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.62 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.62 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.62 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.62 |
| ▸ | GABRE | P78334 | 1/20 | 0.62 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.62 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.62 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.62 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.62 |
| ▸ | CNR1 | P21554 | 2/20 | 0.62 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.61 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30567971 | 1.00 | GABRP (0.62) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL6383779 | 0.92 | CNR1 (0.57) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL8613887 | 0.89 | GABRP (0.63) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL3222980 | 0.88 | GABRP (0.62) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL1231869 | 0.88 | GABRP (0.62) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL12285689 | 0.88 | GABRP (0.62) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL6811482 | 0.87 | SLC6A4 (0.64) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL2268431 | 0.87 | GABRP (0.61) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL9462544 | 0.87 | SLC6A4 (0.65) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL2264033 | 0.85 | GABRP (0.60) | GABRPGABRDGABRA1GABRB1GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111936503-B | Oxazine monoacylglycerol lipase (MAGL) inhibitors | 豪夫迈·罗氏有限公司 | 2023-09-12 | — | — | CN | disclosed |
| US-20230117324-A1 | OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2023-04-20 | — | — | US | disclosed |
| EP-3768684-B1 | OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | HOFFMANN LA ROCHE (CH) | 2023-02-22 | — | — | EP | disclosed |
| US-20210107920-A1 | OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2021-04-15 | — | — | US | disclosed |
| EP-3768684-A1 | OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2021-01-27 | — | — | EP | disclosed |
| CN-111936503-A | Oxazin monoacylglycerol lipase (MAGL) inhibitors | 豪夫迈·罗氏有限公司 | 2020-11-13 | — | — | CN | disclosed |
| EP-3190109-B1 | INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | UNIV LEUVEN KATH (BE) | 2020-02-19 | — | — | EP | disclosed |
| WO-2019180185-A1 | OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2019-09-26 | — | — | WO | disclosed |
| US-20190054068-A1 | Indole Amide Derivatives and Related Compounds for Use in the Treatment of Neurodegenerative Diseases | REMYND (BE) | 2019-02-21 | — | — | US | disclosed |
| US-10117850-B2 | Indole amide derivatives and related compounds for use in the treatment of neurodegenerative diseases | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) | 2018-11-06 | — | — | US | disclosed |
| EP-1315492-A2 | A METHOD FOR TREATING ALLERGIES USING SUBSTITUTED PYRAZOLES | Ortho McNeil Pharmaceutical, Inc. (US) | 2003-06-04 | — | — | EP | disclosed |
| EP-1309592-A2 | SUBSTITUTED PYRAZOLES | Ortho-McNeil Pharmaceutical, Inc. (US) | 2003-05-14 | — | — | EP | disclosed |
| US-6476051-B2 | FOR THERAPY OF PSYCHOSIS, ACUTE MANIA, MILD ANXIETY STATES, OR DEPRESSION IN COMBINATION WITH PSYCHOTIC EPISODES | BRISTOL-MYERS SQUIBB COMPANY | 2002-11-05 | — | — | US | disclosed |
| US-20020147189-A1 | Method for treating allergies using substituted pyrazoles | ORTHO MCNEIL PHARMACEUTICAL, INC. | 2002-10-10 | — | — | US | disclosed |
| EP-1242072-A1 | ANTIPSYCHOTIC HETEROCYCLE COMPOUNDS | Bristol-Myers Squibb Company (US) | 2002-09-25 | — | — | EP | disclosed |
| US-20020072611-A1 | Antipsychotic heterocycle compounds | BRISTOL-MYERS SQUIBB COMPANY | 2002-06-13 | — | — | US | disclosed |
| US-20020040019-A1 | Substituted pyrazoles | ORTHO MCNEIL PHARMACEUTICAL, INC. | 2002-04-04 | — | — | US | disclosed |
| WO-2002020013-A2 | A METHOD FOR TREATING ALLERGIES USING SUBSTITUTED PYRAZOLES | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2002-03-14 | — | — | WO | disclosed |
| WO-2002014317-A2 | SUBSTITUTED PYRAZOLES | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2002-02-21 | — | — | WO | disclosed |
| WO-2001043740-A1 | ANTIPSYCHOTIC HETEROCYCLE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210107920-A1 | OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | MGLL, LPL, LIPC | GABRP 4676/4885GABRD 4500/4885GABRA1 4716/4885 |
| US-20020072611-A1 | Antipsychotic heterocycle compounds | HTR2C, DRD2, HTR1A | GABRP 293/4885GABRD 473/4885GABRA1 371/4885 |
| US-20020040019-A1 | Substituted pyrazoles | CTSS, CTSZ, CTSV | GABRP 2945/4885GABRD 4542/4885GABRA1 4158/4885 |
| US-20190054068-A1 | Indole Amide Derivatives and Related Compounds for Use in the Treatment of Neurodegenerative Diseases | SNCA, MAPT, NLN | GABRP 1431/4885GABRD 4111/4885GABRA1 2582/4885 |
| US-10117850-B2 | Indole amide derivatives and related compounds for use in the treatment of neurodegenerative diseases | SNCA, MAPT, NLN | GABRP 1391/4885GABRD 4075/4885GABRA1 2565/4885 |
| US-20230117324-A1 | OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | MGLL, LPL, LIPC | GABRP 4676/4885GABRD 4500/4885GABRA1 4716/4885 |
| US-20020147189-A1 | Method for treating allergies using substituted pyrazoles | TSLP, IL33, HRH2 | GABRP 1567/4885GABRD 1569/4885GABRA1 942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.